|
|
Volumn 2, Issue 3, 2005, Pages 232-239
|
|
Whither generics? Why major restructuring lies ahead
|
|
Author keywords
Biogenerics; Blockbuster; Competition; Generics; Growth; Over the counter (OTC) switch
|
|
Indexed keywords
AMLODIPINE BESYLATE;
AMLODIPINE PLUS ATORVASTATIN;
AMOXICILLIN PLUS CLAVULANIC ACID;
AMPHETAMINE;
ANTIDEPRESSANT AGENT;
ATORVASTATIN PLUS AMLODIPINE BESYLATE;
AZITHROMYCIN;
CETIRIZINE;
CIPRO XL;
CIPROFLOXACIN;
CITALOPRAM;
DESLORATADINE;
ESCITALOPRAM;
ESOMEPRAZOLE;
EZETIMIBE;
EZETIMIBE PLUS SIMVASTATIN;
FLUOXETINE;
FLUOXETINE PLUS EZETIMIBE;
FLUOXETINE PLUS OLANZAPINE;
GENERIC DRUG;
LORATADINE;
NEW DRUG;
NON PRESCRIPTION DRUG;
OLANZAPINE;
OMEPRAZOLE;
ONDANSETRON;
PRAVASTATIN;
RANITIDINE;
SERTRALINE;
SIMVASTATIN;
TETRAHYDROLIPSTATIN;
UNCLASSIFIED DRUG;
UNINDEXED DRUG;
VENLAFAXINE;
ZANPROL;
ZOCOR HEART PRO;
ZOLPIDEM;
ZOLPIDEM TARTRATE;
ARTICLE;
CHINESE;
CLINICAL TRIAL;
COMMERCIAL PHENOMENA;
COMPETITION;
DEVELOPING COUNTRY;
DRUG FORMULATION;
DRUG INDICATION;
DRUG INDUSTRY;
DRUG MANUFACTURE;
DRUG MARKETING;
DRUG SYNTHESIS;
HUMAN;
INDIAN;
PATENT;
PHARMACEUTICAL CARE;
|
|
EID: 17844372189
PISSN: 17411343
EISSN: None
Source Type: Journal
DOI: 10.1057/palgrave.jgm.4940074 Document Type: Article |
|
Times cited : (7)
|
|
References (0)
|
